Shanghai Junshi Biosciences Co., Ltd.

SHSC:1877 Stock Report

Market Cap: HK$25.5b

Shanghai Junshi Biosciences Past Earnings Performance

Past criteria checks 0/6

Shanghai Junshi Biosciences's earnings have been declining at an average annual rate of -21%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 3.2% per year.

Key information

-21.0%

Earnings growth rate

-16.1%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate3.2%
Return on equity-31.4%
Net Margin-100.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shanghai Junshi Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSC:1877 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,787-1,8031,5101,541
30 Jun 241,619-1,9311,4521,535
31 Mar 241,628-2,0231,4141,686
31 Dec 231,503-2,2831,3991,937
30 Sep 231,222-2,2001,2672,019
30 Jun 231,177-2,4731,2932,271
31 Mar 231,079-2,5351,2432,401
31 Dec 221,453-2,3881,2852,384
30 Sep 222,525-1,9241,3552,282
30 Jun 222,856-1,6431,2592,184
31 Mar 223,039-1,4951,2842,129
31 Dec 214,025-7211,3772,069
30 Sep 213,302-9451,3881,991
30 Jun 213,134-1,0601,4712,016
31 Mar 213,038-1,0621,4102,011
31 Dec 201,595-1,6691,1271,778
30 Sep 201,259-1,4188711,543
30 Jun 201,041-1,0567071,286
31 Mar 20868-600609968
31 Dec 19775-747537946
30 Sep 19528-732429802
30 Jun 19310-735298689
31 Mar 1979-992203662
31 Dec 181-717146538
30 Sep 180-516104453
30 Jun 180-43994377
31 Mar 180-34779289
31 Dec 171-32174275
30 Sep 179-279104172
30 Jun 175-24622239
31 Mar 179-19115658
31 Dec 164-13142122
30 Sep 164-1091380
30 Jun 162-831100
31 Mar 162-71970
31 Dec 153-58840
30 Sep 155-43700
30 Jun 157-27570
31 Mar 156-26500
31 Dec 146-25440

Quality Earnings: 1877 is currently unprofitable.

Growing Profit Margin: 1877 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1877 is unprofitable, and losses have increased over the past 5 years at a rate of 21% per year.

Accelerating Growth: Unable to compare 1877's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1877 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).

Return on Equity

High ROE: 1877 has a negative Return on Equity (-31.36%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 11:01
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Junshi Biosciences Co., Ltd. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Congmin YuanCitic Securities Co., Ltd.
Tan Huan GanCitic Securities Co., Ltd.
Muk Tsz YungCitigroup Inc